Rocket Pharmaceuticals (RCKT) Leases (2018 - 2025)
Historic Leases for Rocket Pharmaceuticals (RCKT) over the last 8 years, with Q3 2025 value amounting to $40.7 million.
- Rocket Pharmaceuticals' Leases fell 502.07% to $40.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.7 million, marking a year-over-year decrease of 502.07%. This contributed to the annual value of $42.4 million for FY2024, which is 483.86% down from last year.
- Latest data reveals that Rocket Pharmaceuticals reported Leases of $40.7 million as of Q3 2025, which was down 502.07% from $41.3 million recorded in Q2 2025.
- In the past 5 years, Rocket Pharmaceuticals' Leases registered a high of $50.3 million during Q1 2021, and its lowest value of $200000.0 during Q1 2023.
- For the 5-year period, Rocket Pharmaceuticals' Leases averaged around $43.1 million, with its median value being $45.1 million (2023).
- Per our database at Business Quant, Rocket Pharmaceuticals' Leases plummeted by 9958.29% in 2023 and then skyrocketed by 2188950.0% in 2024.
- Quarter analysis of 5 years shows Rocket Pharmaceuticals' Leases stood at $48.5 million in 2021, then decreased by 3.75% to $46.7 million in 2022, then decreased by 4.6% to $44.5 million in 2023, then fell by 4.84% to $42.4 million in 2024, then decreased by 3.81% to $40.7 million in 2025.
- Its last three reported values are $40.7 million in Q3 2025, $41.3 million for Q2 2025, and $41.8 million during Q1 2025.